Home » Topics » Disease categories and therapies » Hematologic

Hematologic
RSS

YM-150: favorable biochemical and pharmacological profile reported

Dec. 13, 2006

Novel agents for thrombotic disorders disclosed in recent patents

Dec. 11, 2006

ALX-0081, a Nanobody targeting the von Willebrand Factor, yields positive preclinical results

Dec. 11, 2006

Neose receives milestone payment under Factor VIIa agreement with Novo Nordisk

Nov. 29, 2006

New therapeutic agents for thrombotic disorders disclosed in recent patent literature

Nov. 21, 2006

Study identifies optimal alfimeprase dose for peripheral arterial occlusion

Nov. 20, 2006

DISPERSE studies show consistent platelet aggregation inhibition with AZD-6140

Nov. 17, 2006

Recent patents describe new compounds for thrombotic disorders

Nov. 13, 2006

Rivaroxaban phase III program outlined in stroke prevention and VTE

Nov. 13, 2006

BLA filing for Thrombin

Nov. 8, 2006

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 17, 2026.
Celia trial: data strong, analysts skeptical
BioWorld
Tuesday brought what was arguably the most anticipated presentation of the 2026 Alzheimer’s Association International Conference when Catherine Mummery, head of...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 14, 2026
Voyager’s gene therapy reduces tau levels in AD models
BioWorld Science
At the Alzheimer’s Association International Conference, researchers from Voyager Therapeutics Inc. presented preclinical efficacy data for VY-1706, a blood-brain...
Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability
BioWorld Science
Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...